Create Medicines Raises $122M in Series B Funding

The company plans to use the funding to move its CD19-targeted in vivo CAR-T therapy, CRT-402, into clinical trials for autoimmune diseases, expand development of its dual CAR CD19 x BCMA program, and continue advancing its oncology pipeline.

To date, CREATE has treated more than 50 patients across its in vivo CAR clinical programs, creating one of the largest clinical datasets in the field. The company uses a proprietary mRNA-LNP platform that programs immune cells directly in the body, helping accelerate development from research to clinical trials for both autoimmune diseases and cancer treatments.

"CREATE was built as an iterative immune programming platform in which each clinical study informs and strengthens the next, and it is that work that has revealed the breadth of what in vivo immune programming can address," said Daniel Getts, PhD, Chief Executive Officer of CREATE Medicines. "Our autoimmune and oncology pipeline represents the convergence of years of platform development, clinical execution, and translational learning. We believe our ability to engineer multiple immune cell populations directly in vivo has the potential to reshape treatment paradigms across autoimmune disease and oncology fundamentally, and we look forward to this next chapter of innovation and growth."

“I’m excited to join CREATE at this important stage of the company’s growth,” said Ron Philip. “CREATE has already shown promising in vivo clinical results and built a unique immune programming platform that could change how engineered immune therapies are developed and delivered. The potential to apply this technology to autoimmune diseases and cancer is very exciting.”

Read More:Optura Raises $17.5M in Series A Funding Led by Salesforce Ventures

"I co-founded this company because the science was ahead of the field. More than fifty patients later, it still is. Most in vivo cell therapy companies will struggle to translate science into scalable manufacturing. CREATE owns its manufacturing infrastructure. I am backing CREATE because it can become the next great standalone pharmaceutical company," said Tom Cahill, MD, PhD, Founder and Managing Partner of Newpath Partners.

"CREATE is building one of the most differentiated in vivo immune engineering platforms in the field," said Brian Cuneo. "We believe the company's clinical experience, repeat dose strategy, and broad immune programming capabilities position it to play an important role in the future of autoimmune disease and oncology."

About Create Medicines

Founded by Daniel Getts, Create Medicines is a clinical stage biotech company focused on in vivo immune programming. Its proprietary mRNA-LNP platform is designed to engineer immune cells directly inside the body, including T cells, NK cells and myeloid cells, to create scalable off-the-shelf immunotherapies. The company is developing in vivo CAR therapies for autoimmune diseases, and cancer.

Read More:Synthetic Raises $10M in Seed Funding Led by Khosla Ventures